B97.4
Conditions
Interventions
Group 1: In this study, saliva and blood samples will be collected from all enrolled participants at three time points during routine blood draws in the outpatient clinic: immediately before RSV vacci
Sponsors
Charite- Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: all patients who are vaccinated as part of routine care
Exclusion criteria
Exclusion criteria: -Inability to fully comprehend the informed consent, and minors. -Known infection with human immunodeficiency virus (HIV), presence of active -hepatitis C or active hepatitis B infection, as well as any uncontrolled active systemic infection. -Any concurrent medical or psychological condition that may impair the ability to provide consent. -Individuals detained by a public authority under legal mandate. -Lack of willingness to consent to the storage of pseudonymized medical data related to the study. -Lack of willingness to permit the collection of study-relevant personal data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In the saliva of RSV-vaccinated patients, bacteria can be detected that bind antibodies against the prefusion F protein (both commercial antibodies and antibodies cloned from the patients). | — |
Secondary
| Measure | Time frame |
|---|---|
| The presence of a specific bacterial strain in the saliva of RSV-vaccinated patients correlates with the antibody level in the blood against the prefusion F protein. The presence of a specific bacterial strain in the saliva of RSV-vaccinated patients correlates with the antibody level in the saliva against the prefusion F protein. The presence of a specific bacterial strain in the saliva of RSV-vaccinated patients correlates with the T-cell response against the prefusion F protein. | — |
Countries
Germany
Contacts
Public ContactEva Schrezenmeier
Charité-Universitätsmedizin Berlin
Outcome results
None listed